Literature DB >> 22940487

Histopathologic differences account for racial disparity in uterine cancer survival.

David Smotkin1, Nicole S Nevadunsky, Kimala Harris, Mark H Einstein, Yiting Yu, Gary L Goldberg.   

Abstract

OBJECTIVE: The incidence for uterine cancers has been reported to be higher among white women, whereas mortality is higher among black women. Reasons for the higher mortality among black women are not completely understood. The aim of our study is to examine the relationship between race/ethnicity, histopathologic subtype, and survival in uterine cancer.
METHODS: We abstracted socio-demographic, treatment, and survival data for all women who were diagnosed with uterine cancer at Montefiore Medical Center from January 1999 through December 2009. Pathology records were reviewed.
RESULTS: 984 patients were identified. Racial/ethnic distribution was 382 (39%) white, 308 (31%) black, 232 (24%) Hispanic, and 62 (6.3%) other races, mixed, or unknown. 592 (60%) patients had endometrioid histology. Blacks were much more likely than whites to have non-endometrioid histologies (p<0.001), including papillary serous, carcinosarcoma, and leiomyosarcoma. Blacks and Hispanics were at least as likely as whites to receive either chemotherapy or radiation therapy. The hazard ratio for death for black versus white patients was 1.94 (p<0.001) when all histological subtypes were included. The hazard ratio for Hispanics for death was 1.2 (p=0.32) compared to whites. However, when patients were divided into endometrioid and non-endometrioid histological subtypes, there was no significant difference in survival by race/ethnicity.
CONCLUSION: Black patients with uterine cancer are much more likely to die and are much more likely to have non-endometrioid histologies than white patients. There are no differences in survival among white, black, or Hispanic women with uterine cancer, after control for histological subtype.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22940487      PMCID: PMC3828997          DOI: 10.1016/j.ygyno.2012.08.025

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  14 in total

1.  FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics.

Authors:  S Pecorelli; J L Benedet; W T Creasman; J H Shepherd
Journal:  Int J Gynaecol Obstet       Date:  1999-01       Impact factor: 3.561

2.  Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features.

Authors:  M E Sherman; P Bitterman; N B Rosenshein; G Delgado; R J Kurman
Journal:  Am J Surg Pathol       Date:  1992-06       Impact factor: 6.394

3.  Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women.

Authors:  R P Matthews; J Hutchinson-Colas; M Maiman; R G Fruchter; E J Gates; D Gibbon; J C Remy; A Sedlis
Journal:  Gynecol Oncol       Date:  1997-05       Impact factor: 5.482

4.  An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).

Authors:  Amanda Nickles Fader; David Starks; Paola A Gehrig; Angeles Alvarez Secord; Heidi E Frasure; David M O'Malley; Erin R Tuller; Peter G Rose; Laura J Havrilesky; Kathleen N Moore; Warner K Huh; Allison E Axtell; Joseph L Kelley; Kristine M Zanotti
Journal:  Gynecol Oncol       Date:  2009-08-26       Impact factor: 5.482

5.  Uterine papillary serous carcinoma: patterns of metastatic spread.

Authors:  B A Goff; D Kato; R A Schmidt; M Ek; J A Ferry; H G Muntz; J M Cain; H K Tamimi; D C Figge; B E Greer
Journal:  Gynecol Oncol       Date:  1994-09       Impact factor: 5.482

6.  The National Cancer Data Base report on endometrial carcinoma in African-American women.

Authors:  M L Hicks; J L Phillips; G Parham; N Andrews; W B Jones; H M Shingleton; H R Menck
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

7.  Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time.

Authors:  Jason D Wright; Jessica Fiorelli; Peter B Schiff; William M Burke; Amanda L Kansler; Carmel J Cohen; Thomas J Herzog
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

8.  Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma.

Authors:  M Hendrickson; J Ross; P Eifel; A Martinez; R Kempson
Journal:  Am J Surg Pathol       Date:  1982-03       Impact factor: 6.394

9.  Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths.

Authors:  Stefanie M Ueda; Daniel S Kapp; Michael K Cheung; Jacob Y Shin; Kathryn Osann; Amreen Husain; Nelson N Teng; Jonathan S Berek; John K Chan
Journal:  Am J Obstet Gynecol       Date:  2008-02       Impact factor: 8.661

10.  Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999.

Authors:  Sandra E Brooks; Min Zhan; Timothy Cote; Claudia R Baquet
Journal:  Gynecol Oncol       Date:  2004-04       Impact factor: 5.482

View more
  10 in total

Review 1.  Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology.

Authors:  Yvonne Collins; Kevin Holcomb; Eloise Chapman-Davis; Dineo Khabele; John H Farley
Journal:  Gynecol Oncol       Date:  2014-01-07       Impact factor: 5.482

Review 2.  Molecular cues on obesity signals, tumor markers and endometrial cancer.

Authors:  Danielle Daley-Brown; Gabriela M Oprea-Ilies; Regina Lee; Roland Pattillo; Ruben R Gonzalez-Perez
Journal:  Horm Mol Biol Clin Investig       Date:  2015-01

Review 3.  Disparities in gynecologic cancer incidence, treatment, and survival: a narrative review of outcomes among black and white women in the United States.

Authors:  Mary Towner; J Julie Kim; Melissa A Simon; Daniela Matei; Dario Roque
Journal:  Int J Gynecol Cancer       Date:  2022-07-04       Impact factor: 4.661

Review 4.  Current and Emerging Prognostic Biomarkers in Endometrial Cancer.

Authors:  Kelechi Njoku; Chloe E Barr; Emma J Crosbie
Journal:  Front Oncol       Date:  2022-04-22       Impact factor: 5.738

Review 5.  Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States.

Authors:  B Long; F W Liu; R E Bristow
Journal:  Gynecol Oncol       Date:  2013-05-23       Impact factor: 5.482

Review 6.  Reasons to Reconsider Risk Associated With Power Morcellation of Uterine Fibroids.

Authors:  Burkhard Helmke; Joern Bullerdiek; Carsten Holzmann; Wolfgang Kuepker; Birgit Rommel
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

Review 7.  Genetics of endometrial cancer.

Authors:  Ayelet Shai; Yakir Segev; Steven A Narod
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

8.  Racial disparities in survival among women with endometrial cancer in an equal access system.

Authors:  Amie B Park; Kathleen M Darcy; Chunqiao Tian; Yovanni Casablanca; Jill K Schinkel; Lindsey Enewold; Katherine A McGlynn; Craig D Shriver; Kangmin Zhu
Journal:  Gynecol Oncol       Date:  2021-07-27       Impact factor: 5.482

Review 9.  Disparities in Gynecological Malignancies.

Authors:  Sudeshna Chatterjee; Divya Gupta; Thomas A Caputo; Kevin Holcomb
Journal:  Front Oncol       Date:  2016-02-22       Impact factor: 6.244

10.  Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma.

Authors:  Anne R Van Arsdale; Rebecca C Arend; Maria J Cossio; Britt K Erickson; Yanhua Wang; David W Doo; Charles A Leath; Gary L Goldberg; Gloria S Huang
Journal:  Cancer Med       Date:  2018-02-18       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.